Corrigendum to "Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

1. An integrated machine learning and mendelian randomization approach identifies SERPING1 as a prognostic biomarker associated with CD8 + T-cell infiltration in DLBCL.Discover oncology · 2026
   Article
2. T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma.World journal of clinical cases · 2022
   Article

Corrections and comments

• Erratum for
  Genetic Mutations of Tim-3 Ligand and Exhausted Tim-32020

Authors and funding

17 authors at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract